NEUROENDOCRINE TUMORS

This trial compares two FDA-approved catheters used during TACE, a procedure that delivers chemotherapy directly to liver tumors. Twelve participants with liver cancer or neuroendocrine tumors will receive two TACE procedures, each using a different catheter. The goal is to see w…

This phase 2 study tests a personalized immune cell therapy called tumor-infiltrating lymphocytes (TIL) in 20 people with advanced solid cancers (like stomach, colon, or pancreatic cancer) that have not responded to standard treatments. Patients first receive chemotherapy to prep…

This phase 2 study tests the drug entrectinib in over 500 people with advanced solid tumors that have specific gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors and control the disease. Participants have various cancer types, including lu…

This study tests a combination of two drugs, pembrolizumab and lenvatinib, in people with a rare and aggressive form of prostate cancer called neuroendocrine prostate cancer that has spread. The goal is to see if this treatment can slow or stop tumor growth. About 45 participants…

This early study tests whether giving the drug Lutathera directly into the liver artery is safe and practical for people with neuroendocrine tumors that have spread mainly to the liver. Ten participants will receive two doses into the liver artery followed by two standard IV dose…

This phase 2 study tests a drug called 212Pb-DOTAMTATE, which delivers radiation directly to neuroendocrine tumor cells. It includes 69 adults whose tumors have grown despite standard treatments. The goal is to see if the drug shrinks tumors and to check for side effects.

This early-phase study tests a new two-drug combination for people with advanced neuroendocrine tumors (NETs) that have stopped responding to standard treatments. The drugs are cabozantinib (a targeted therapy pill) and Lu-177 DOTATATE (a radioactive treatment that seeks out tumo…

This study tests whether the immunotherapy drug avelumab can help prevent Merkel cell carcinoma, a rare skin cancer, from returning after initial treatment. About 122 adults with stage I to III Merkel cell carcinoma will receive either avelumab or a placebo. The main goal is to s…

This phase 3 trial tests whether a radioactive drug called 177Lu-Edotreotide (PRRT) works better than the daily pill everolimus for people with advanced neuroendocrine tumors of the gut or pancreas that can't be removed by surgery. About 324 participants are randomly assigned to …

This Phase 2 trial is testing whether combining two immunotherapy drugs, ipilimumab and nivolumab, can shrink or control rare cancers that are known to respond to immunotherapy. The study includes 240 people with advanced biliary tract, neuroendocrine, gynecologic, or MSI-H solid…

This phase II trial is testing a combination of chemotherapy (carboplatin and etoposide) with immunotherapy (pembrolizumab), followed by maintenance therapy with pembrolizumab and lenvatinib, in 20 people with advanced high-grade neuroendocrine tumors who have not had prior chemo…

This phase II trial is testing an oral drug called CVM-1118 in 34 people with advanced neuroendocrine tumors that have not responded to standard treatments. The drug aims to slow tumor growth and improve disease control. Participants take the pill twice daily, with a possible dos…

This phase II trial tests whether combining the immunotherapy drug nivolumab with the chemotherapy drug temozolomide can shrink tumors in people with small-cell lung cancer that has returned or not responded to treatment, or advanced neuroendocrine tumors. About 55 participants w…

This study tests a treatment called Lu-DOTATATE, which delivers radiation directly to neuroendocrine tumor cells. About 195 people with tumors that have gotten worse will receive up to 4 cycles of this therapy, with doses adjusted based on individual scans and blood tests. The ma…

This early-phase study tests a new radioactive drug, [212Pb] VMT-α-NET, in 24 adults with advanced neuroendocrine tumors that have not responded to other treatments. The main goal is to find a safe dose for future studies, not to treat the disease. Participants receive up to two …

This Phase 3 trial tests a radioactive drug called 177Lu-Edotreotide against standard chemotherapy for people with aggressive neuroendocrine tumors of the gut or pancreas. The drug targets tumor cells and delivers radiation directly. About 259 participants will be followed to see…

This Phase 3 study tested a radioactive drug called Lutetium-177 oxodotreotide against a high dose of the standard drug octreotide in 196 people with advanced neuroendocrine tumors that had stopped responding to treatment. The main goal was to see if the radioactive drug could de…

This study tests whether a new type of PET/CT scan, using a radioactive tracer called 68Ga-DOTATOC, can find neuroendocrine tumors (NETs) and similar tumors more safely and accurately than current imaging methods. About 800 people with known or suspected NETs will receive the sca…

This pilot study is testing the world's first total-body PET/CT scanner (EXPLORER) to see if it can improve cancer imaging. Researchers will scan 9 people with prostate cancer, breast cancer, or neuroendocrine tumors using FDA-approved radiotracers. The goal is to measure how wel…

This study compares three different PET/CT scans (68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG) in 50 people with metastatic neuroendocrine tumors. The goal is to see if all tumors show up on the standard scan or if some are missed, which could change treatment. Participants will get …

This study is not testing a new treatment. Instead, it follows people who already received experimental cell therapies (like growing immune cells from their tumors or blood) in earlier NCI Surgery Branch trials. The goal is to monitor their health for up to 15 years, as required …

This study looks at 500 people with advanced neuroendocrine tumors to see if starting with surufatinib or somatostatin analogs leads to better outcomes. Researchers will compare how long the cancer is controlled with each sequence. The goal is to provide real-world evidence to gu…

This pilot study is testing whether combining two different PET scans can give doctors a clearer picture of neuroendocrine tumors (NETs) in the gut. The scans measure how tumors take up different tracers, which may reveal whether a tumor is slow-growing or aggressive. The goal is…

This study aims to create better guidelines for reading PET scans in people with neuroendocrine tumors. Researchers will compare new criteria against the current standard to see which better predicts if a tumor shrinks, grows, or stays the same. The study involves 11 participants…

This study follows over 1,000 adults with advanced neuroendocrine tumors who have already been treated with Lutathera. Researchers are tracking long-term side effects, including the risk of new cancers, and overall survival. The goal is to better understand the drug's safety over…

This study follows over 2,500 people with neuroendocrine tumors (NETs) to understand their symptoms and how treatments are chosen. Participants fill out surveys about quality of life and care experiences over 18 months. Researchers will link this to medical records to find which …